<DOC>
	<DOCNO>NCT02011022</DOCNO>
	<brief_summary>* The pharmacokinetics MTX assess regard relevance several different patient specific factor 291 pediatric patient , administer high dose MTX . Population pharmacokinetics MTX analysis perform use nonlinear mixed effect model .</brief_summary>
	<brief_title>Pharmacokinetic Analysis High Dose Methotrexate Pediatric Lymphoblastic Malignancies</brief_title>
	<detailed_description>- Methotrexate ( MTX ) one critical component treat form acute lymphoblastic leukemia ( ALL ) , common pediatric cancer . Unfortunately , high dose MTX several undesirable side effect MTX toxicity vastly differ patient patient . - The pharmacokinetics MTX assess regard relevance several different patient specific factor 291 pediatric patient , administer high dose MTX . Population pharmacokinetics MTX analysis perform use nonlinear mixed effect model . - The final model validate use nonparametric bootstrap analysis . Body surface area ( BSA ) , pre-hydration , baseline serum creatinine 24 h creatinine clearance rate statistically significant covariates distributional volume ( V ) renal clearance ( CL ) . Herein , first report analysis importance series patient factor pharmacokinetics MTX one-compartment model . Using data , establish efficient population pharmacokinetic model MTX , use predict safe clinical application MTX especially child ALL .</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Acute lymphoblastic leukemia nonhodgkin 's lymphoma young 18 year old Non lymphoblastic malignancy older 18 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Methotrexate ,</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Model</keyword>
</DOC>